For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Immune Modulator

LL-37

Also known as: Cathelicidin

LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide (starting with two leucines) cleaved from the hCAP-18 precursor. It has broad-spectrum antimicrobial activity and immunomodulatory roles, but is also implicated in the pathogenesis of autoimmune and inflammatory skin diseases including psoriasis, rosacea, and lupus. Not FDA-approved; research-use only.

Where to buy · live market data

Who's worth your money for LL-37

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 17 scored sellers

$7.00/mg

$34.99 · 5mg · 99.0% purity

1 COA
Buy Code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$4.50/mg

$45.00 · 10mg · 99.9% purity

Most tested

8 independent COAs on file

$13.00/mg

$65.00 · 5mg · 99.8% purity

Average price

$10.94/mg

Sellers

45

45-day trend

-17.9%

34 of 45 sellers have a current price· 12 stale hidden· 5 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch LL-37

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About LL-37

CAS

154947-66-7

Molecular formula

C205H340N60O53

Sequence

LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

Typical dose range

100–400 mcg/day subcutaneous

Half-life

~4–6 hours (tissue-dependent; limited formal PK data for native LL-37)

Independent evidence

COAs for LL-37

59 third-party tests across 20 vendors. Each card links to the full report.

All 59 COAs for LL-37 →
Measured purity 91.1%–100.0% across 48 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.38 %
Sep 2026
Janoshik Analytical Limited

For

LL-37

by CertaPeptides· batch CP-2608-LLT5

✓ Vendor-published
99.31 %
Sep 2026
Chromate Moderate

For

LL-37

by Ruo Bio· batch LL3-H-003

COA on file
Aggregated · 3rd-party listing
99.00 %
Sep 2026
Ethos Analytics Strong

For

LL-37

by Glacier Aminos· batch LL5GA-01

✓ Vendor-published
99.81 %
Aug 2026
Janoshik Analytical Limited

For

LL-37

by Verified Peptides· batch LL0526030C

COA on file
Aggregated · 3rd-party listing
99.65 %
Jul 2026
Freedom Diagnostics Moderate

For

LL-37

by Peptide Plugs· batch 175-01-DK

Aggregated · 3rd-party listing
99.60 %
Jun 2026
ILS Labs Strong

For

LL-37

by Ion Peptide· batch L375-06092026

✓ Vendor-published
99.83 %
Jun 2026
ILS Laboratories

For

LL-37

by Ion Peptide· batch L375-06092026

COA on file
Aggregated · 3rd-party listing
99.64 %
May 2026
Janoshik Analytical Limited · HPLC

For

LL-37

by Verified Peptides· batch LL05260305C

✓ Vendor-published
99.64 %
May 2026
Janoshik Analytical Limited

For

LL-37

by Verified Peptides· batch LL05260305C

COA on file
Aggregated · 3rd-party listing
99.64 %
May 2026
Janoshik Analytical Limited

For

LL-37

by Verified Peptides

Aggregated · 3rd-party listing
94.08 %
May 2026
Janoshik Analytical Limited

For

LL-37

by Verified Peptides· batch LL025602005C

Aggregated · 3rd-party listing
91.08 %
May 2026
Freedom Diagnostics Moderate

For

LL-37

by Real Peptides· batch Black Cap

Aggregated · 3rd-party listing
99.94 %
Mar 2026
Kovera Labs

For

LL-37

by Ion Peptide· batch LL375-03232026

✓ Vendor-published
99.94 %
Mar 2026
Kovera Labs

For

LL-37

by Ion Peptide· batch LL375-03232026

COA on file
Aggregated · 3rd-party listing
99.96 %
Mar 2026
Freedom Diagnostics Moderate

For

LL-37

by Modern Research Peptides· batch GCEMHK0226

Aggregated · 3rd-party listing
99.50 %
Feb 2026
Janoshik Analytical Limited

For

LL-37

by EZ Peptides· batch EZP-LL371002172026-01

✓ Vendor-published
99.50 %
Feb 2026
Janoshik Analytical Limited

For

LL-37

by EZ Peptides· batch EZP-LL37100217-2026-01

COA on file
Aggregated · 3rd-party listing
99.47 %
Feb 2026
Vanguard Laboratory Strong

For

LL-37

by Peptidology· batch 1669

✓ Vendor-published
99.93 %
Jan 2026
Freedom Diagnostics Moderate

For

LL-37

by Alpha Omega· batch LL05-0116206J-1

COA on file
✓ Vendor-published
99.04 %
Jan 2026
Janoshik Analytical Limited

For

LL-37

by Ruo Bio

COA on file
Aggregated · 3rd-party listing
99.93 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

LL-37

by Simple Peptide· batch L1-05-01162026-J

✓ Vendor-published
99.93 %
Jan 2026
Freedom Diagnostics Moderate

For

LL-37

by Alpha Omega· batch LL10-370112326-1

COA on file
Aggregated · 3rd-party listing
99.83 %
Jan 2026
Freedom Diagnostics Moderate

For

LL-37

by Southern Aminos· batch LL050126A

Aggregated · 3rd-party listing
99.93 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

LL-37

by Simple Peptide· batch LL10-37011220236-J

Research depth

20 citations indexed for LL-37

All research on LL-37 →

review · 2026

Apoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling

This review summarizes current knowledge on the role of human cathelicidin LL-37 in the regulation of apoptosis. LL-37 can modulate programmed cell death pathways, exerting either proapoptotic or antiapoptotic effects depending on various factors, such as cell type and peptide concentration.

Study · 2026

Association of Porphyromonas gingivalis peptidylarginine deiminase with CitH3, LL-37, and ACPA in periodontitis and rheumatoid arthritis

Background Porphyromonas gingivalis peptidyl-arginine deiminase (PPAD) enzyme has been implicated in rheumatoid arthritis (RA) pathogenesis through protein citrullination and its potential contribution to neutrophil-associated inflammatory responses and anti-citrullinated protein antibody (ACPA) autoimmunity.

review · 2026

LL-37-MRGPRX2-Mast Cell Signaling in Rosacea: Current Evidence and Directions for Human Studies

This critical narrative review examines evidence relevant to LL-37-Mas-related G protein-coupled receptor X2 (MRGPRX2)-mast-cell signaling in rosacea and considers the relevance of these findings to future human studies.

Study · 2026

Coordination chemistry and antimicrobial activity of LL-37, its C-terminal fragment, and a peptidomimetic analogue

Human cathelicidin LL-37 is an antimicrobial peptide naturally present in saliva that plays an important role in host defence against bacterial and fungal pathogens. Although LL-37 is known to bind Cu(II) and Zn(II) ions, the corresponding coordination modes have remained unresolved.

review · 2026

LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease

Human cathelicidin peptide LL-37 is encoded by the CAMP gene and plays a key role in innate immunity. It maintains intestinal homeostasis through antibacterial, immunomodulation, and tissue repair functions.

review · 2026

LL-37-based oral antimicrobial therapeutics: translational challenges and future directions-a narrative review

LL-37 is an antimicrobial peptide involved in antimicrobial defence, inflammatory regulation, tissue repair, and bone regeneration in the oral cavity. Salivary and gingival crevicular fluid LL-37 levels are associated with disease activity and treatment responses.